PolyPeptide attracts takeover interest from EQT, KKR, Bloomberg News reports

PolyPeptide AG

10/04/2026 18:41

April 10 (Reuters) - Swiss contract drugmaker PolyPeptide Group AG PPGN.S is attracting potential takeover interest from private equity firms including EQT AB EQTAB.ST and KKR & Co. KKR.N, Bloomberg News reported on Friday, citing people with knowledge of the matter.

Here are some details:

Advent has also been studying a possible acquisition of PolyPeptide, the report said.

Any buyout firm pursuing a take-private deal could seek to collaborate with Swedish businessman Frederik Paulsen Jr., PolyPeptide's billionaire controlling shareholder, according to Bloomberg.

Shares of PolyPeptide have risen nearly 20% this year, increasing the company's market value to about 1 billion Swiss francs ($1.3 billion).

Deliberations are ongoing and there’s no certainty they will lead to a transaction, according to the report.

The private equity companies declined to comment, Bloomberg said, while a spokesperson for PolyPeptide told the news agency that the company remained focused on executing its strategic plan.

(Reporting by Hyunsu Yim in Barcelona; Editing by Kirsten Donovan)

((Hyunsu.Yim@thomsonreuters.com;))